Takeda Pharmaceutical Company Limited
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 15 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/30 | ¥53.12 | ¥71.65 | +34.9% |
| 2026/05/13 | ¥-24.01 | ¥-15.31 | +36.3% |
| 2026/01/28 | ¥43.14 | ¥65.74 | +52.4% |
| 2025/10/29 | ¥33.80 | ¥-7.83 | -123.2% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
23.1M | +0.07% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
15.3M | +2.45% | |
|
Capital World Growth & Income Fund
|
13.2M | -4.12% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
11.6M | +1.21% | |
|
Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd.
|
10.2M | 0.00% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
6.9M | +6.22% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
2.1M | +9.92% | |
|
Paradigm Asset Management Company, LLC
|
1.6K | 0.00% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥100 | -49.5% |
| 2025 | ¥198 | +3.1% |
| 2024 | ¥192 | +4.3% |
| 2023 | ¥184 | +2.2% |
| 2022 | ¥180 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥3,569,006M | ¥4,027,478M | ¥4,263,762M | ¥4,581,551M |
| Gross Profit | ¥2,462,160M | ¥2,783,406M | ¥2,837,084M | ¥3,001,334M |
| Operating Income | ¥546,043M | ¥587,812M | ¥366,165M | ¥486,061M |
| Pretax Income | ¥425,003M | ¥492,063M | ¥172,326M | ¥312,395M |
| Net Income | ¥230,059M | ¥317,017M | ¥144,067M | ¥107,928M |
| EPS | ¥145.87 | ¥201.94 | ¥91.16 | ¥67.23 |
| Operating Margin | 15.30% | 14.60% | 8.59% | 10.61% |
| Balance Sheet | ||||
| Total Assets | ¥13,178,018M | ¥13,957,750M | ¥15,108,792M | ¥14,248,344M |
| Total Equity | ¥5,683,019M | ¥6,354,122M | ¥7,273,264M | ¥6,935,084M |
| Total Liabilities | ¥7,494,999M | ¥7,603,628M | ¥7,835,528M | ¥7,313,260M |
| Cash | ¥849,695M | ¥533,530M | ¥457,800M | ¥385,113M |
| Interest-bearing Debt | ¥4,345,411M | ¥4,382,341M | ¥4,843,752M | ¥4,515,265M |
| Equity Ratio | 43.12% | 45.52% | 48.14% | 48.67% |
| D/E Ratio | 0.76 | 0.69 | 0.67 | 0.65 |
| Cash Flow | ||||
| Operating CF | ¥1,123,105M | ¥977,156M | ¥716,344M | ¥1,057,182M |
| Investing CF | -¥198,125M | -¥607,102M | -¥463,862M | -¥367,060M |
| Financing CF | -¥1,070,265M | -¥709,148M | -¥354,416M | -¥751,425M |
| Free CF | ¥937,068M | ¥343,467M | ¥235,614M | ¥677,557M |
| Efficiency | ||||
| ROE | 4.05% | 4.99% | 1.98% | 1.56% |
| ROA | 1.75% | 2.27% | 0.95% | 0.76% |
Latest IR Information
-
ORZEYFUL (generic name: obeporepton) FDA approval in the United States News Release
With the FDA approval of ORZEYFUL (obeporepton), it is approved as the first orexin receptor agonist for NT1 treatment. After DEA classification review is completed, it will be launched in the U.S. market via specialty pharmacies. Impact on full-year consolidated...
Read more -
[Takeda Pharmaceutical] Q1 FY2026 Financial Results | Revenue of ¥1.2199 trillion (YoY +10.2%)
Takeda Pharmaceutical's Q1 FY2026 financial results show revenue of ¥1.2199 trillion (YoY +10.2%) and operating profit of ¥201.4 billion (△3.1%), with net income of ¥113.3 billion (△8.9%). Attention is needed on future performance trends.
Read more -
Notice on the Completion of Payment for New Share Issuance and Treasury Stock Disposition under the Long-Term Incentive Plan for Our Group Employees Outside Japan
Payment completion for new share issuance and disposition of treasury stock under the overseas group employee Long-Term Incentive Plan. Reflects changes in issued shares and disposed shares; impact on future performance is expected to be minor.
Read more -
【Takeda Pharmaceutical】Juliet Kim Appointed as President and CEO ｜ June 2026
Takeda Pharmaceutical has appointed Juliet Kim as President and CEO, planning three new product launches and five late-stage development projects within the next 12 months.
Read more -
Takeda Pharmaceutical's Long-term Incentive System Introduction and Share Buyback｜June 2026
Takeda Pharmaceutical plans to implement the issuance of 16,989,076 new shares and share buyback on July 8, 2026, raising approximately 8.58 billion yen. This is part of a long-term incentive system for overseas employees, with beneficiaries including 10,557 employees of...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥6,375
Rating Score: 1.81 (Based on 15 analysts)
※1=Strong Buy, 5=Strong Sell
Takeda (TSE:4502) Stock Looks Undervalued As AI Drug Discovery Progress Builds - Yahoo Finance ↗
Company Information
About
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
